Statistical analysis in radiopharmaceutical clinical trials demands specialized methodologies that account for the unique nature of imaging biomarkers, radioactive pharmacokinetics, and dosimetry endpoints, where conventional pharmaceutical statistical approaches often fall short. Protheragen offers comprehensive biostatistical analysis and clinical study reporting services specifically designed for investigator-initiated radiopharmaceutical trials, ensuring rigorous quantitative interpretation from protocol design through regulatory submission.
Investigator-initiated trials in radiopharmaceutical development generate complex, multimodal datasets that require sophisticated statistical frameworks extending far beyond conventional clinical trial biostatistics. These trials incorporate imaging-derived quantitative biomarkers—such as standardized uptake values (SUV), tumor-to-background ratios (TBR), metabolic tumor volumes (MTV), and time-activity curves—alongside traditional clinical endpoints including progression-free survival (PFS), objective response rate (ORR), and safety parameters graded by CTCAE v5.0. The statistical analysis must accommodate the longitudinal nature of imaging data, the correlation structure of repeated measurements within patients across multiple treatment cycles, and the integration of patient-specific dosimetry calculations derived from serial quantitative PET or SPECT imaging.
Fig 1. Comparative assessments of developing and reporting of study objective types and models. (Dwivedi, Alok Kumar, 2022)
The preparation of clinical study reports (CSRs) for radiopharmaceutical trials presents additional complexity, requiring the integration of statistical results from imaging endpoints, biodistribution assessments, radiation dosimetry, pharmacokinetic modeling, and conventional safety and efficacy analyses into a coherent regulatory narrative. These reports must align with ICH E3 guidelines while addressing radiopharmaceutical-specific considerations such as absorbed dose-response relationships, organ-at-risk exposure profiles, and imaging-based tumor response criteria like RECIP (Response Evaluation Criteria in PSMA Imaging) or PERCIST (PET Response Criteria in Solid Tumors). The biostatistician serves as a critical bridge between raw clinical data and regulatory decision-making, ensuring that every analysis is methodologically sound, pre-specified, and interpretable to both scientific and regulatory audiences.
Protheragen delivers integrated biostatistical analysis and clinical study reporting services that bridge the gap between complex radiopharmaceutical data and regulatory-grade evidence. Our biostatistics team combines deep expertise in imaging endpoint analysis, dosimetry modeling, and oncology trial design with rigorous adherence to CDISC standards, ICH guidelines, and FDA/EMA regulatory expectations, ensuring that every analysis plan, table, figure, and listing supports robust scientific conclusions and streamlined regulatory submissions.
We develop comprehensive, protocol-aligned SAPs that pre-specify all statistical methodologies, analysis populations (ITT, PP, safety), endpoint definitions, handling of missing data, multiplicity control strategies, and interim analysis boundaries. Our SAPs address radiopharmaceutical-specific considerations including imaging endpoint analysis, dosimetry correlation modeling, and dose-response relationships, finalized prior to database lock per regulatory requirements.
We provide expert consultation on trial design, randomization schemes, and sample size calculations powered to detect clinically meaningful differences in imaging biomarkers, tumor response rates, or survival endpoints. Our designs incorporate radiopharmaceutical-specific assumptions including expected effect sizes for SUV changes, TBR improvements, and dosimetry-based dose-response thresholds.
Our biostatisticians apply specialized methodologies for quantitative imaging data, including mixed-effects models for repeated SUV and TBR measurements, metabolic tumor volume change analysis, time-activity curve modeling, and PERCIST/RECIP response classification. We develop validated analysis datasets (ADaM) integrating imaging biomarker data with clinical outcomes for comprehensive efficacy assessment.
We conduct comprehensive safety analyses including adverse event incidence rates, CTCAE v5.0 graded toxicity summaries, dose-limiting toxicity (DLT) assessments, and radiation exposure profiling. Efficacy analyses encompass tumor response rates (RECIST 1.1, PERCIST, RECIP), progression-free survival, overall survival, and exploratory biomarker subgroup analyses.
Protheragen combines specialized radiopharmaceutical expertise with rigorous biostatistical methodology to deliver analysis and reporting services that transform complex multimodal data into actionable, regulatory-grade evidence. Our integrated approach ensures seamless alignment between statistical planning, data analysis, and clinical interpretation throughout the trial lifecycle.
Whether you are designing the statistical framework for your first radiopharmaceutical investigator-initiated trial or preparing for regulatory submission of a completed study, Protheragen is ready to provide the biostatistical expertise and reporting precision your program demands. Contact us today to discuss how our integrated statistical analysis and clinical study reporting services can strengthen your evidence package and accelerate your regulatory pathway. Reach out to us to schedule a consultation with our biostatistics team.
Reference